{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:21Z","timestamp":1781650641212,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guangzhou Basic and Applied Basic Research Project","award":["2024A04J4777"],"award-info":[{"award-number":["2024A04J4777"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403264"],"award-info":[{"award-number":["82403264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2024A1515013004"],"award-info":[{"award-number":["2024A1515013004"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangzhou Major Clinical Projects","award":["2023P-ZD12"],"award-info":[{"award-number":["2023P-ZD12"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The second-line treatment for recurrent or metastatic cervical cancer remains uncertain and controversial. Sacituzumab govitecan, the first-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), has demonstrated promising efficacy and safety in several clinical trials for cervical cancer. However, real-world clinical data on sacituzumab govitecan combined with immunotherapy remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 73-year-old woman diagnosed with stage IIIC1r (FIGO 2018) cervical squamous cell carcinoma underwent concurrent chemoradiotherapy as the primary treatment. The disease recurred 20 months later; thus 3 cycles of chemotherapy combined with bevacizumab and additional 5 cycles of bevacizumab monotherapy were recommended. Although the patient achieved complete response in both the primary treatment and the first recurrence treatment, the second recurrence was detected 15 months later. The patient underwent 6 cycles of sacituzumab govitecan combined with tislelizumab and additional 6 cycles of tislelizumab monotherapy. Partial response was achieved with an 88.1% reduction in target lesion size, along with a PFS of 9 months and an ongoing OS of 13 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sacituzumab govitecan combined with tislelizumab demonstrated potential treatment response in this case. However, further prospective clinical trials are warranted to validate its efficacy and safety in the difficult second-line setting of recurrent or metastatic cervical cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12905-026-04481-4","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:04:07Z","timestamp":1776823447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sacituzumab govitecan combined with tislelizumab as second-line therapy for recurrent or metastatic cervical cancer: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6214-8308","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaofang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1179-3723","authenticated-orcid":false,"given":"Dongyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"4481_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"4481_CR2","doi-asserted-by":"publisher","first-page":"155136","DOI":"10.1016\/j.prp.2024.155136","volume":"254","author":"G Yadav","year":"2024","unstructured":"Yadav G, Srinivasan G, Jain A. Cervical cancer: Novel treatment strategies offer renewed optimism. Pathol Res Pract. 2024;254:155136. https:\/\/doi.org\/10.1016\/j.prp.2024.155136.","journal-title":"Pathol Res Pract"},{"key":"4481_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353. https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006.","journal-title":"J Natl Cancer Cent"},{"key":"4481_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.6004\/jnccn.2025.0057","volume":"23","author":"NR Abu-Rustum","year":"2025","unstructured":"Abu-Rustum NR, Campos SM, Amarnath S, et al. Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23:549\u201373. https:\/\/doi.org\/10.6004\/jnccn.2025.0057.","journal-title":"J Natl Compr Canc Netw"},{"key":"4481_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41571-024-00977-w","volume":"22","author":"AA Francoeur","year":"2025","unstructured":"Francoeur AA, Monk BJ, Tewari KS. Treatment advances across the cervical cancer spectrum. Nat Rev Clin Oncol. 2025;22:182\u201399. https:\/\/doi.org\/10.1038\/s41571-024-00977-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"4481_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med. 2024;391:44\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2313811.","journal-title":"N Engl J Med"},{"key":"4481_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2112187","volume":"386","author":"KS Tewari","year":"2022","unstructured":"Tewari KS, Monk BJ, Vergote I, et al. Survival with Cemiplimab in Recurrent Cervical Cancer. N Engl J Med. 2022;386:544\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2112187.","journal-title":"N Engl J Med"},{"key":"4481_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","volume":"25","author":"MK Anastasio","year":"2024","unstructured":"Anastasio MK, Shuey S, Davidson BA. Antibody-Drug Conjugates in Gynecologic Cancers. Curr Treat Options Oncol. 2024;25:1\u201319. https:\/\/doi.org\/10.1007\/s11864-023-01166-0.","journal-title":"Curr Treat Options Oncol"},{"key":"4481_CR9","doi-asserted-by":"publisher","first-page":"e75864","DOI":"10.1371\/journal.pone.0075864","volume":"8","author":"T Liu","year":"2013","unstructured":"Liu T, Liu Y, Bao X, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS ONE. 2013;8:e75864. https:\/\/doi.org\/10.1371\/journal.pone.0075864.","journal-title":"PLoS ONE"},{"key":"4481_CR10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746\u201356. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005.","journal-title":"Ann Oncol"},{"key":"4481_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"4481_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab Govitecan: First Approval. Drugs. 2020;80:1019\u201325. https:\/\/doi.org\/10.1007\/s40265-020-01337-5.","journal-title":"Drugs"},{"key":"4481_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/s41598-020-58009-3","volume":"10","author":"B Zeybek","year":"2020","unstructured":"Zeybek B, Manzano A, Bianchi A, et al. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Sci Rep. 2020;10:973. https:\/\/doi.org\/10.1038\/s41598-020-58009-3.","journal-title":"Sci Rep"},{"key":"4481_CR14","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ygyno.2024.07.038","volume":"190","author":"J An","year":"2024","unstructured":"An J, Li G, Zhang Y, et al. Sacituzumab govitecan for Chinese patients with recurrent\/metastatic cervical cancer: Interim analysis of the phase II basket study EVER-132-003. Gynecol Oncol. 2024;190:S22. https:\/\/doi.org\/10.1016\/j.ygyno.2024.07.038.","journal-title":"Gynecol Oncol"},{"key":"4481_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-023-11735-z","volume":"23","author":"C Nie","year":"2023","unstructured":"Nie C, Xu W, Guo Y, et al. Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study. BMC Cancer. 2023;23:1239. https:\/\/doi.org\/10.1186\/s12885-023-11735-z.","journal-title":"BMC Cancer"},{"key":"4481_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/abt\/tbaf017","volume":"8","author":"L Yin","year":"2025","unstructured":"Yin L, Zhou S, Zhang H, et al. Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors. Antib Ther. 2025;8:262\u201374. https:\/\/doi.org\/10.1093\/abt\/tbaf017.","journal-title":"Antib Ther"},{"key":"4481_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol"},{"key":"4481_CR18","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","volume":"31","author":"SM Tolaney","year":"2025","unstructured":"Tolaney SM, Cardillo TM, Chou C-C, et al. The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors. Clin Cancer Res. 2025;31:1390\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1525.","journal-title":"Clin Cancer Res"},{"key":"4481_CR19","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","volume":"17","author":"TM Cardillo","year":"2011","unstructured":"Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17:3157\u201369. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2939.","journal-title":"Clin Cancer Res"},{"key":"4481_CR20","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1016\/j.annonc.2024.08.778","volume":"35","author":"J Wang","year":"2024","unstructured":"Wang J, An R, Huang Y, et al. 716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Ann Oncol. 2024;35:S548\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.778.","journal-title":"Ann Oncol"},{"key":"4481_CR21","unstructured":"MK-2870-020. http:\/\/www.chinadrugtrials.org.cn\/index.html. Accessed 11 Aug 2025."},{"key":"4481_CR22","unstructured":"BAT-8008-001-CR. http:\/\/www.chinadrugtrials.org.cn\/index.html. Accessed 11 Aug 2025."},{"key":"4481_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.18632\/oncotarget.27342","volume":"11","author":"S Lopez","year":"2020","unstructured":"Lopez S, Perrone E, Bellone S, et al. Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget. 2020;11:560\u201370. https:\/\/doi.org\/10.18632\/oncotarget.27342.","journal-title":"Oncotarget"},{"key":"4481_CR24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord J-P, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019;37:1470\u20138. https:\/\/doi.org\/10.1200\/JCO.18.01265.","journal-title":"J Clin Oncol"},{"key":"4481_CR25","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.19.00739","volume":"37","author":"RW Naumann","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T, et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I\/II CheckMate 358 Trial. J Clin Oncol. 2019;37:2825\u201334. https:\/\/doi.org\/10.1200\/JCO.19.00739.","journal-title":"J Clin Oncol"},{"key":"4481_CR26","doi-asserted-by":"publisher","first-page":"1113369","DOI":"10.3389\/fimmu.2023.1113369","volume":"14","author":"X Zheng","year":"2023","unstructured":"Zheng X, Gu H, Cao X, et al. Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers. Front Immunol. 2023;14:1113369. https:\/\/doi.org\/10.3389\/fimmu.2023.1113369.","journal-title":"Front Immunol"},{"key":"4481_CR27","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1200\/JCO.22.02835","volume":"42","author":"P Grivas","year":"2024","unstructured":"Grivas P, Pouessel D, Park CH, et al. Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. J Clin Oncol. 2024;42:1415\u201325. https:\/\/doi.org\/10.1200\/JCO.22.02835.","journal-title":"J Clin Oncol"},{"issue":"25","key":"4481_CR28","doi-asserted-by":"publisher","first-page":"02890","DOI":"10.1016\/j.jtho.2025.10.016","volume":"S1556\u20130864","author":"M Reck","year":"2025","unstructured":"Reck M, Patel JD, Gray JE, et al. First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS\u2009<\u200950% and \u2265\u200950% Cohorts of the EVOKE-02 Study. J Thorac Oncol. 2025;S1556\u20130864(25):02890\u20134. https:\/\/doi.org\/10.1016\/j.jtho.2025.10.016.","journal-title":"J Thorac Oncol"},{"key":"4481_CR29","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1200\/JCO.2025.43.16_suppl.8529","volume":"43","author":"W Fang","year":"2025","unstructured":"Fang W, Wang Q, Cheng Y, et al. Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study. JCO. 2025;43:8529\u20138529. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8529.","journal-title":"JCO"},{"key":"4481_CR30","doi-asserted-by":"publisher","first-page":"1230395","DOI":"10.3389\/fphar.2023.1230395","volume":"14","author":"Y Wei","year":"2023","unstructured":"Wei Y, Zhang R, Yu C, et al. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study. Front Pharmacol. 2023;14:1230395. https:\/\/doi.org\/10.3389\/fphar.2023.1230395.","journal-title":"Front Pharmacol"},{"key":"4481_CR31","doi-asserted-by":"publisher","first-page":"A23","DOI":"10.1136\/ijgc-2024-IGCS.25","volume":"34","author":"H Gu","year":"2024","unstructured":"Gu H, Zhou J, Wang J, et al. PT002\/#568 Cadonilimab in combination with disitamab vedotin or nab-paclitaxel in the treatment of recurrent or metastatic cervical cancer: a prospective, double-cohort, multi-center, open-label, phase II clinical study (AK001). Int J Gynecol Cancer. 2024;34:A23\u20134. https:\/\/doi.org\/10.1136\/ijgc-2024-IGCS.25.","journal-title":"Int J Gynecol Cancer"},{"key":"4481_CR32","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.22.02887","volume":"41","author":"PH O\u2019Donnell","year":"2023","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023;41:4107\u201317. https:\/\/doi.org\/10.1200\/JCO.22.02887.","journal-title":"J Clin Oncol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04481-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04481-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:31:39Z","timestamp":1781649099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04481-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4481"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04481-4","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report complied with the Declaration of Helsinki. Formal ethical approval was not required to report this case by the Institutional Review Board of Sun Yat-sen Memorial Hospital. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}